Stockreport

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” [Yahoo! Fi...

Tenax Therapeutics, Inc.  (TENX) 
Last tenax therapeutics, inc. earnings: 11/14 04:31 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.tenaxthera.com
PDF due to heart failure with preserved ejection fraction (PH-HFpEF) and the potential role for levosimendan in treating this prevalent, fatal disease Experts will explain [Read more]